Recombinant interferon gamma in hairy cell leukemia, multiple myelome, and Waldestrom's macroglobulinemia
Department of Clinical Immunology and Biological Therapy, M. D. Anderson Hospital and Tumor Institute, Houston. American Journal of Hematology
(Impact Factor: 3.8).
09/1988; 29(1):1-4. DOI: 10.1002/ajh.2830290102
Fifteen patients with multiple myeloma, five with hairy cell leukemia, and five with Waldenstrom's macroglobulinemia were treated with recombinant interferon gamma (rINF-gamma) to determine the antitumor activity of this agent. The rIFN-gamma was administered by daily intramuscular injection at doses ranging from 0.125 to 0.5 mg/m2. No responses were observed in patients with multiple myeloma, although in one patient the disease has remained stable for over 16 months. Minimal improvement in some hematologic indexes were observed in three of five patients with hairy cell leukemia. One partial remission and one minor response were documented in two of the five patients with Waldenstrom's macroglobulinemia. In five patients, an increase in normal serum immunoglobulins was observed. These results suggest that there is only minimal activity of rIFN-gamma as a single agent in neoplasms of B-cell origin.
Available from: Graziella Bellone
- "e l s e v i e r . c o m / l o c a t e / i n t i m p IFN-γ as conventional chemotherapy against different types of tumor, including melanoma , glioma , small-cell lung , bladder , and breast  cancers, and in hematological , ovarian , renal , and gastrointestinal   malignancies, has had limited success, with severe dose-dependent toxicity. This suggests that invivo doses route, and/or administration schedule may be inappropriate in vivo. "
[Show abstract] [Hide abstract]
ABSTRACT: Natural killer (NK) cells are innate immune-system lymphocytes capable of killing tumor cells. They secrete cytokines, including interferon (IFN)-γ, which participate in shaping the initial inflammatory and downstream adaptive immune responses. Its potent immunoregulatory action means that IFN-γ might be beneficial in cases of tumor rejection, but its severe side-effects limit clinical applications. This pilot study compared low-dose IFN-γ prepared by sequential-kinetic-activation (SKA), with standard-dose recombinant (r) IFN-γ, in terms of ex-vivo cytotoxic activity of peripheral blood (PB)-NK cells from colorectal carcinoma (CRC) patients. This was tested against the NK-sensitive K562 cell line and the less-sensitive human CRC Caco-2 and HT-29 cell lines. Twenty primitive non-metastatic CRC patients, five metastatic CRC patients, and thirteen healthy donors were enrolled. PB lymphocytes (PBLs) were exposed to medium alone, SKA-IFN-γ (0.25fg/ml) or rIFN-γ (1ng/ml). NK cell cytolytic activity was examined via short-term (51)Cr-release. Pretreatment of PBL from non-metastatic patients with SKA-IFN-γ caused a significant increase in NK cell cytotoxicity, compared to those from normal donors, although less markedly than pretreatment with rIFN-γ against all three cell lines. In contrast, PBLs from metastatic CRC patients displayed significantly decreased NK-cell activity and responsiveness to both rIFN-γ and SKA-IFN-γ treatments. These results demonstrate in principle the immunomodulatory capacity of low-dose SKA-IFN-γ, and might open the door to the possibility of generating a novel, safe, and feasible approach to enhancing NK-cell antitumor activity in early-stage CRC patients.
International immunopharmacology 12/2013; 19(1). DOI:10.1016/j.intimp.2013.12.011 · 2.47 Impact Factor
Available from: onlinelibrary.wiley.com
- "DISCUSSION There is no standard salvage treatment for WM patients resistant to alkylator-based therapy. Doxorubicin (Claman et al, 1980), high-dose corticosteroids (Jane & Salem, 1988) and interferon (Quesada et al, 1988) have all been evaluated in patients with resistant WM. However, response rates are typically low and responses only brief. "
[Show abstract] [Hide abstract]
ABSTRACT: This phase II clinical trial evaluated bolus cladribine as a single agent in Waldenström macroglobulinaemia (WM).
Cladribine was administered to 20 patients at a dose of 0.12 mg/kg/d by 2 h intravenous infusion for 5 consecutive days at monthly intervals for three courses. Partially responding patients were continued on therapy until maximal response and/or prohibitive toxicity, to a maximum of eight courses. Complete responders were treated with one additional course of cladribine.
After a median of three courses of cladribine, all 20 patients were evaluable; one achieved a complete response (CR) (5%) and 10 achieved a partial response (PR) (50%). The median duration of response follow-up was 28 months (range 1–37 months). Four of 7 (57%) untreated and 7/13 (54%) previously treated patients responded. The major toxicity encountered was myelosuppression with 60% of patients demonstrating grade 3 or 4 neutropenia. Non-haematological toxicities included two patients with herpes zoster and two patients with non-melanoma skin cancers. At a median follow-up duration of 20 months, 17 patients remain alive and three have died.
We confirm that bolus cladribine is an effective and safe method of drug delivery in WM patients. Recommendations regarding the equivalence of the continuous infusion and bolus methods in untreated patients requires further study. Bolus cladribine is more convenient and less costly than infusional cladribine since it obviates the need for central catheters and infusional devices.
British Journal of Haematology 11/1998; 103(3):690 - 695. DOI:10.1046/j.1365-2141.1998.01069.x · 4.71 Impact Factor
Available from: Henrik Hjorth-Hansen
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.